Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18176/jiaci.1041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Lancet Respir Med
January 2025
Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK. Electronic address:
Article Synopsis
Thymic Stromal Lymphopoietin (TSLP): Evidence in Respiratory Epithelial-driven Diseases Including Chronic Rhinosinusitis with Nasal Polyps.
Curr Allergy Asthma Rep
December 2024
Rhinology Unit and Smell Clinic, Department of Otorhinolaryngology, Hospital Clinic, FRCB- IDIBAPS, Universitat de Barcelona, CIBERES. Barcelona, Catalonia, Spain.
Purpose Of The Review: Thymic stromal lymphopoietin (TSLP) is increasingly recognized for its pivotal role in the pathogenesis of various epithelial-driven chronic inflammatory diseases. This review navigates the existing evidence on TSLP, with a particular focus on asthma, before delving into the current understanding of its role in chronic rhinosinusitis with nasal polyps (CRSwNP). We explore the role of TSLP in the pathogenesis of asthma and CRSwNP, two conditions often interconnected and collectively referred to as"Global Airway Disease".
View Article and Find Full Text PDFExploratory analysis of the economically justifiable price of tezepelumab for asthma severe in Colombia.
J Asthma
December 2024
Department of Pharmacology and Toxicology, University of Antioquia, Medellín, Colombia.
Introduction: Asthma severe imposes important economic burden on health systems, especially with the incorporation of new drugs. Recently, tezepelumab has been approved to prevent exacerbations in patients. This study explores the economically justifiable price of tezepelumab for preventing exacerbations in patients with severe asthma.
View Article and Find Full Text PDFBiologics treatment for eosinophilic chronic rhinosinusitis complicated by bronchial asthma: Narrative review.
Respir Investig
December 2024
Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-1 Kusunokicho, Chuo-ku, Kobe, Hyogo 650-0017, Japan. Electronic address:
There are 4 subtypes of chronic rhinosinusitis (CRS): eosinophilic CRS with nasal polyps (ECRSwNP), ECRS without NPs (ECRSsNP), non-ECRSwNP, and non-ECRSsNP. Most ECRS cases are categorized as ECRSwNP, and the number of patients with ECRSwNP has recently increased. ECRS is associated mainly with helper T-cell type 2 inflammation and eosinophils.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!